Posted 15th October 2020 by Nicholas Noakes
Ahead of the Global Pharma R&D AI, Data Science and Informatics Summit we sat down with Claire Biot to talk about her work to provide life science companies & professionals with a scientific and business platform to imagine sustainable innovations, capable of improving patient & physician experience in the age of precision medicine.
Posted 23rd October 2019 by Joshua Sewell
Cyclica is a Toronto-based biotech that leverages artificial intelligence and computational biophysics to reshape the drug discovery process. We spoke to their Chief Scientific Officer Andreas Windemuth.
Posted 30th September 2019 by Joshua Sewell
Global Engage spoke to Scott Kahn ahead of the 3rdGlobal Pharma R&D Informatics and AI Congress. Scott is the CIO of Luna PBC, the entity that manages LunaDNA: a community-owned data-sharing resource. Their conversation was recorded as a podcast, which can be found here.
This is the second half of that conversation, where Scott discusses the challenges of distributive ledger technologies such as Blockchain, and their intersection with AI for Pharma R&D.
Posted 23rd September 2019 by Joshua Sewell
Ahead of the 3rd Global Pharma R&D Informatics and AI Congress, Global Engage spoke to Scott Kahn, CIO of LunaPBC. LunaPBC is the company that manages LunaDNA: a community-owned data-sharing resource. Their conversation was recorded as a podcast, which can be found here.
In the first half of the conversation, Scott discusses the benefits of distributive ledger technologies such as Blockchain for Pharma R&D.
Posted 9th September 2019 by Joshua Sewell
As Chief Data Officer for the OSTHUS Group, Eric Little co-founded LeapAnalysis, a new approach to AI, data integration and analytics.
LeapAnalysis is the first fully federated and virtualised search and analytics engine that runs on semantic metadata. It allows users to combine semantic models (ontologies) with machine learning algorithms to provide customers with unparalleled flexibility in utilizing their data.
Posted 19th August 2019 by Jane Williams
e-Therapeutics, an Oxford-based company, is using its network-driven drug discovery (NDD) technology to embrace the inherent complexity of biology, providing a novel and productive method for the discovery of new medicines.
Jonny Wray is the head of Discovery Informatics at e-Therapeutics. Trained as a computational neuroscientist, he is responsible for building the NDD technology. We spoke to him ahead of his presentation at the Global Pharma R&D Informatics & AI Congress.
Posted 2nd August 2019 by Jane Williams
With a background in pharmacology, toxicology, molecular cell biology and genetics, Rangaprasad Sarangarajan joined BERG Health in 2010 as head of R&D.
In the initial years of the company, he aided in the conception, design, and implementation of the paradigm of looking at human biology, use of technology to generate molecular signatures, and the use of artificial intelligence-based analytics for understanding the complexity of biology, identifying of targets, and developing of drugs, and its utility in clinical development.
Posted 26th July 2019 by Jane Williams
This article was originally published on Open Targets and is republished with kind permission.
For many cancers we don’t have an effective treatment option, and worse still, a lot of the therapies that we use are just not good enough. We need better cancer therapies, and we need them now.
The reason we need new therapies is actually the reason why I got into cancer research. It goes back to when I was only 17 when my Mam was diagnosed with acute myeloid leukemia (AML). She went through her treatment, chemotherapy, with another 12 patients, and unfortunately she was the only one who survived.